3SC009
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 12, 2026
Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=100 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Monotherapy • New P1 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1